Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF. Sameni M, et al. Among authors: graveel cr. Clin Cancer Res. 2016 Feb 15;22(4):923-34. doi: 10.1158/1078-0432.CCR-15-0187. Epub 2015 Oct 2. Clin Cancer Res. 2016. PMID: 26432786 Free PMC article.
Met decoys: will cancer take the bait?
Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Zhang YW, et al. Cancer Cell. 2004 Jul;6(1):5-6. doi: 10.1016/j.ccr.2004.07.003. Cancer Cell. 2004. PMID: 15261136 Free article.
UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB. Gilani RA, et al. Among authors: graveel cr. Clin Cancer Res. 2016 Oct 15;22(20):5087-5096. doi: 10.1158/1078-0432.CCR-15-2158. Epub 2016 May 6. Clin Cancer Res. 2016. Retraction in: Clin Cancer Res. 2020 Apr 1;26(7):1777. doi: 10.1158/1078-0432.CCR-20-0653 PMID: 27154914 Retracted.
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR. Linklater ES, et al. Among authors: graveel cr. Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065. Oncotarget. 2016. PMID: 27655711 Free PMC article.
MET in human cancer: germline and somatic mutations.
Tovar EA, Graveel CR. Tovar EA, et al. Among authors: graveel cr. Ann Transl Med. 2017 May;5(10):205. doi: 10.21037/atm.2017.03.64. Ann Transl Med. 2017. PMID: 28603720 Free PMC article. Review.
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. Engstrom LD, et al. Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765324 Clinical Trial.
34 results